The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated th...

Full description

Saved in:
Bibliographic Details
Published in:Front Oncol
Main Authors: Marwitz, Sebastian, Turkowski, Kati, Nitschkowski, Dörte, Weigert, Andreas, Brandenburg, Julius, Reiling, Norbert, Thomas, Michael, Reck, Martin, Drömann, Daniel, Seeger, Werner, Rabe, Klaus F., Savai, Rajkumar, Goldmann, Torsten
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2020
Subjects:
Oncology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985561/
https://ncbi.nlm.nih.gov/pubmed/32039023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01550
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items